RESUMEN
This article highlights trends and changes in lung and heart-lung transplantation in the United States from 1999 to 2008. While adult lung transplantation grew significantly over the past decade, rates of heart-lung and pediatric lung transplantation have remained low. Since implementation of the lung allocation score (LAS) donor allocation system in 2005, decreases in the number of active waiting list patients, waiting times for lung transplantation and death rates on the waiting list have occurred. However, characteristics of recipients transplanted in the LAS era differed from those transplanted earlier. The proportion of candidates undergoing lung transplantation for chronic obstructive pulmonary disease decreased, while increasing for those with pulmonary fibrosis. In the LAS era, older, sicker and previously transplanted candidates underwent transplantation more frequently compared with the previous era. Despite these changes, when compared with the pre-LAS era, 1-year survival after lung transplantation did not significantly change after LAS inception. The long-term effects of the change in the characteristics of lung transplant recipients on overall outcomes for lung transplantation remain unknown. Continued surveillance and refinements to the LAS system will affect the distribution and types of candidates transplanted and hopefully lead to improved system efficiency and outcomes.
Asunto(s)
Trasplante de Corazón-Pulmón/estadística & datos numéricos , Trasplante de Pulmón , Enfermedad Pulmonar Obstructiva Crónica/mortalidad , Fibrosis Pulmonar/cirugía , Donantes de Tejidos/estadística & datos numéricos , Listas de Espera , Adulto , Niño , Trasplante de Corazón-Pulmón/mortalidad , Humanos , Pulmón/cirugía , Trasplante de Pulmón/mortalidad , Trasplante de Pulmón/estadística & datos numéricos , Trasplante de Pulmón/tendencias , Enfermedad Pulmonar Obstructiva Crónica/patología , Enfermedad Pulmonar Obstructiva Crónica/cirugía , Fibrosis Pulmonar/epidemiología , Fibrosis Pulmonar/mortalidad , Factores de Tiempo , Resultado del Tratamiento , Estados Unidos/epidemiologíaRESUMEN
This article highlights trends and changes in lung and heart-lung transplantation in the United States from 1998 to 2007. The most significant change over the last decade was implementation of the Lung Allocation Score (LAS) allocation system in May 2005. Subsequently, the number of active wait-listed lung candidates declined 54% from pre-LAS (2004) levels to the end of 2007; there was also a reduction in median waiting time, from 792 days in 2004 to 141 days in 2007. The number of lung transplants performed yearly increased through the decade to a peak of 1 465 in 2007; the greatest single year increase occurred in 2005. Despite candidates with increasingly higher LAS scores being transplanted in the LAS era, recipient death rates have remained relatively stable since 2003 and better than in previous years. Idiopathic pulmonary fibrosis became the most common diagnosis group to receive a lung transplant in 2007 while emphysema was the most common diagnosis in previous years. The number of retransplants and transplants in those aged > or =65 performed yearly have increased significantly since 1998, up 295% and 643%, respectively. A decreasing percentage of lung transplant recipients are children (3.5% in 2007, n = 51). With LAS refinement ongoing, monitoring of future impact is warranted.
Asunto(s)
Trasplante de Corazón-Pulmón/estadística & datos numéricos , Trasplante de Pulmón/estadística & datos numéricos , Listas de Espera , Adulto , Distribución por Edad , Cateterismo Cardíaco/estadística & datos numéricos , Niño , Enfisema/epidemiología , Enfisema/cirugía , Trasplante de Corazón-Pulmón/mortalidad , Humanos , Trasplante de Pulmón/mortalidad , Fibrosis Pulmonar/epidemiología , Fibrosis Pulmonar/cirugía , Sistema de Registros , Asignación de Recursos/estadística & datos numéricos , Análisis de Supervivencia , Sobrevivientes , Estados Unidos , United States Dept. of Health and Human ServicesRESUMEN
Living donor liver transplantation (LDLT) may have better immunological outcomes compared to deceased donor liver transplantation (DDLT). The aim of this study was to analyze the incidence of acute cellular rejection (ACR) after LDLT and DDLT. Data from the adult-to-adult living donor liver transplantation (A2ALL) retrospective cohort study on 593 liver transplants done between May 1998 and March 2004 were studied (380 LDLT; 213 DDLT). Median LDLT and DDLT follow-up was 778 and 713 days, respectively. Rates of clinically treated and biopsy-proven ACR were compared. There were 174 (46%) LDLT and 80 (38%) DDLT recipients with >/=1 clinically treated episodes of ACR, whereas 103 (27%) LDLT and 58 (27%) DDLT recipients had >/=1 biopsy-proven ACR episode. A higher proportion of LDLT recipients had clinically treated ACR (p = 0.052), but this difference was largely attributable to one center. There were similar proportions of biopsy-proven rejection (p = 0.97) and graft loss due to rejection (p = 0.16). Longer cold ischemia time was associated with a higher rate of ACR in both groups despite much shorter median cold ischemia time in LDLT. These data do not show an immunological advantage for LDLT, and therefore do not support the application of unique posttransplant immunosuppression protocols for LDLT recipients.
Asunto(s)
Selección de Donante , Rechazo de Injerto/epidemiología , Trasplante de Hígado/métodos , Donadores Vivos , Donantes de Tejidos , Enfermedad Aguda , Estudios de Cohortes , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
This article highlights trends in heart and lung transplantation between 1997 and 2006, drawing on data from the OPTN and SRTR. The total number of candidates actively awaiting heart transplantation declined by 45% over the last decade, dropping from 2414 patients in 1997 to 1327 patients in 2006. The overall death rates among patients awaiting heart transplantation declined over the same period. The distribution of recipients among the different status groups at the time of heart transplantation changed little between the inception of the new classification system in 1999 and 2005. Deaths in the first year after heart transplantation have steadily decreased. At the end of 2006, 2885 candidates were awaiting a lung transplant, up 10% from the 1997 count. The median time-to-transplant for listed patients decreased by 87% over the decade, dropping from 1053 days in 1997 to 132 days in 2006. Selection for listing and transplantation has shifted toward more urgent patients since the May 2005 implementation of a new lung allocation system based on survival benefit and urgency rather than waiting time. Only 31 heart-lung transplants were performed in 2006, down from a high of 62 in 1997.
Asunto(s)
Trasplante de Corazón/estadística & datos numéricos , Trasplante de Corazón/tendencias , Trasplante de Pulmón/estadística & datos numéricos , Trasplante de Pulmón/tendencias , Adolescente , Adulto , Distribución por Edad , Niño , Supervivencia de Injerto , Trasplante de Corazón/inmunología , Trasplante de Corazón/mortalidad , Humanos , Terapia de Inmunosupresión/métodos , Inmunosupresores/uso terapéutico , Trasplante de Pulmón/inmunología , Trasplante de Pulmón/mortalidad , Persona de Mediana Edad , Asignación de Recursos/métodos , Asignación de Recursos/tendencias , Análisis de Supervivencia , Resultado del Tratamiento , Estados Unidos , Listas de EsperaRESUMEN
We examined mortality and recurrence of hepatocellular carcinoma (HCC) among 106 transplant candidates with cirrhosis and HCC who had a potential living donor evaluated between January 1998 and February 2003 at the nine centers participating in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL). Cox regression models were fitted to compare time from donor evaluation and time from transplant to death or HCC recurrence between 58 living donor liver transplant (LDLT) and 34 deceased donor liver transplant (DDLT) recipients. Mean age and calculated Model for End-Stage Liver Disease (MELD) scores at transplant were similar between LDLT and DDLT recipients (age: 55 vs. 52 years, p = 0.21; MELD: 13 vs. 15, p = 0.08). Relative to DDLT recipients, LDLT recipients had a shorter time from listing to transplant (mean 160 vs. 469 days, p < 0.0001) and a higher rate of HCC recurrence within 3 years than DDLT recipients (29% vs. 0%, p = 0.002), but there was no difference in mortality or the combined outcome of mortality or recurrence. LDLT recipients had lower relative mortality risk than patients who did not undergo LDLT after the center had more experience (p = 0.03). Enthusiasm for LDLT as HCC treatment is dampened by higher HCC recurrence compared to DDLT.
Asunto(s)
Carcinoma Hepatocelular/epidemiología , Neoplasias Hepáticas/epidemiología , Trasplante de Hígado/efectos adversos , Donadores Vivos/estadística & datos numéricos , Complicaciones Posoperatorias/epidemiología , Donantes de Tejidos/estadística & datos numéricos , Adulto , Anciano , Cadáver , Estudios de Cohortes , Femenino , Humanos , Neoplasias Hepáticas/patología , Trasplante de Hígado/mortalidad , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Complicaciones Posoperatorias/patología , Estudios Retrospectivos , Análisis de Supervivencia , Factores de Tiempo , Listas de EsperaRESUMEN
This article examines the Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients data on heart and lung transplantation in the United States from 1996 to 2005. The number of heart transplants performed and the size of the heart waiting list continued to drop, reaching 2126 and 1334, respectively, in 2005. Over the decade, post-transplant graft and patient survival improved, as did the chances for survival while on the heart waiting list. The number of deceased donor lung transplants increased by 78% since 1996, reaching 1407 in 2005 (up 22% from 2004). There were 3170 registrants awaiting lung transplantation at the end of 2005, down 18% from 2004. Death rates for both candidates and recipients have been dropping, as has the time spent waiting for a lung transplant. Other lung topics covered are living donation, recent surgical advances and changes in immunosuppression regimens. Heart-lung transplantation has declined to a small (33 procedures in 2005) but important need in the United States.
Asunto(s)
Trasplante de Corazón/estadística & datos numéricos , Trasplante de Corazón-Pulmón/estadística & datos numéricos , Trasplante de Pulmón/estadística & datos numéricos , Obtención de Tejidos y Órganos/estadística & datos numéricos , Cadáver , Etnicidad , Supervivencia de Injerto , Asignación de Recursos para la Atención de Salud/estadística & datos numéricos , Trasplante de Corazón/mortalidad , Trasplante de Corazón/tendencias , Trasplante de Corazón-Pulmón/mortalidad , Trasplante de Corazón-Pulmón/tendencias , Humanos , Terapia de Inmunosupresión/métodos , Trasplante de Pulmón/mortalidad , Trasplante de Pulmón/tendencias , Sistema de Registros , Análisis de Supervivencia , Donantes de Tejidos , Obtención de Tejidos y Órganos/métodos , Obtención de Tejidos y Órganos/tendencias , Estados Unidos , Listas de EsperaRESUMEN
This article reviews trends in thoracic organ transplantation based on OPTN/SRTR data from 1995 to 2004. The number of active waiting list patients for heart transplants continues to decline, primarily because there are fewer patients with coronary artery disease listed for transplantation. Waiting times for heart transplantation have decreased, and waiting list deaths also have declined, from 259 per 1000 patient-years at risk in 1995 to 156 in 2004. Fewer heart transplants were performed in 2004 than in 1995, but adjusted patient survival increased to 88% at 1 year and 73% at 5 years. Emphysema, idiopathic pulmonary fibrosis and cystic fibrosis were the most common indications among lung transplant recipients in 2004. Waiting time for lung transplantation decreased between 1999 and 2004. Waiting list mortality decreased to 134 per 1000 patient-years at risk in 2004. One-year survival following transplantation has improved significantly in the past decade. The number of combined heart-lung transplants performed in the United States remains low, with only 39 performed in 2004. Overall unadjusted survival, at 58% at 1 year and 40% at 5 years, is lower among heart-lung recipients than among either heart or lung recipients alone.
Asunto(s)
Trasplante de Corazón/historia , Trasplante de Corazón/tendencias , Trasplante de Pulmón/historia , Trasplante de Pulmón/tendencias , Adolescente , Adulto , Anciano , Niño , Supervivencia de Injerto , Trasplante de Corazón/estadística & datos numéricos , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Terapia de Inmunosupresión , Trasplante de Pulmón/estadística & datos numéricos , Persona de Mediana Edad , Listas de EsperaRESUMEN
This article reviews the development of the new U.S. lung allocation system that took effect in spring 2005. In 1998, the Health Resources and Services Administration of the U.S. Department of Health and Human Services published the Organ Procurement and Transplantation Network (OPTN) Final Rule. Under the rule, which became effective in 2000, the OPTN had to demonstrate that existing allocation policies met certain conditions or change the policies to meet a range of criteria, including broader geographic sharing of organs, reducing the use of waiting time as an allocation criterion and creating equitable organ allocation systems using objective medical criteria and medical urgency to allocate donor organs for transplant. This mandate resulted in reviews of all organ allocation policies, and led to the creation of the Lung Allocation Subcommittee of the OPTN Thoracic Organ Transplantation Committee. This paper reviews the deliberations of the Subcommittee in identifying priorities for a new lung allocation system, the analyses undertaken by the OPTN and the Scientific Registry for Transplant Recipients and the evolution of a new lung allocation system that ranks candidates for lungs based on a Lung Allocation Score, incorporating waiting list and posttransplant survival probabilities.
Asunto(s)
Asignación de Recursos para la Atención de Salud/métodos , Trasplante de Pulmón/métodos , Obtención de Tejidos y Órganos/métodos , Adolescente , Adulto , Anciano , Niño , Donación Directa de Tejido , Supervivencia de Injerto , Humanos , Persona de Mediana Edad , Asignación de Recursos , Estados Unidos , Listas de EsperaRESUMEN
Measuring and monitoring performance--be it waiting list and posttransplant outcomes by a transplant center, or organ donation success by an organ procurement organization and its partnering hospitals--is an important component of ensuring good care for people with end-stage organ failure. Many parties have an interest in examining these outcomes, from patients and their families to payers such as insurance companies or the Centers for Medicare and Medicaid Services; from primary caregivers providing patient counseling to government agencies charged with protecting patients. The Scientific Registry of Transplant Recipients produces regular, public reports on the performance of transplant centers and organ procurement organizations. This article explains the statistical tools used to prepare these reports, with a focus on graft survival and patient survival rates of transplant centers--especially the methods used to fairly and usefully compare outcomes of centers that serve different populations. The article concludes with a practical application of these statistics--their use in screening transplant center performance to identify centers that may need remedial action by the OPTN/UNOS Membership and Professional Standards Committee.
Asunto(s)
Trasplante de Órganos/estadística & datos numéricos , Obtención de Tejidos y Órganos/estadística & datos numéricos , Adolescente , Adulto , Factores de Edad , Anciano , Supervivencia de Injerto , Humanos , Persona de Mediana Edad , Modelos Estadísticos , Trasplante de Órganos/métodos , Sistema de Registros , Riesgo , Donantes de Tejidos , Obtención de Tejidos y Órganos/métodos , Resultado del Tratamiento , Listas de EsperaRESUMEN
The human homolog of the Saccharomyces cerevisiae cell division control 27 gene (CDC27) was mapped to human chromosome 17q12-q21 using a panel of human/rodent somatic cell hybrids and localized distal to the breast cancer susceptibility gene, BRCA1, using a panel of radiation hybrids. The radiation hybrid panel indicates that the most likely position of human CDC27 on human chromosomes 17 is between the marker D17S409 and the beta 3 subunit of integrin (ITGB3). Further confirmation of this localization comes from the sequence tagged site (STS) mapping of human CDC27 to the same yeast artificial chromosomes (YACs) positive for ITGB3. The estimated distance between ITGB3 and human CDC27 is less than 600 kb.